StockNews.AI
SAGE
StockNews.AI
112 days

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

1. Sage Therapeutics reports strong growth in ZURZUVAE shipments and revenue for Q1 2025. 2. CEO emphasizes commitment to expand access for women with postpartum depression.

2m saved
Insight
Article

FAQ

Why Bullish?

The strong revenue growth indicates robust demand for ZURZUVAE, positively influencing SAGE's market position.

How important is it?

Strong performance metrics can drive investor confidence and influence SAGE's stock positively.

Why Short Term?

Immediate revenue growth in Q1 suggests potential for upcoming earnings reports and stock price movement.

Related Companies

VRTXPTONAVLR
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team's disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi.

Related News